These seemingly inconsistent data may derive from the multi-faceted immune responses associated with Type 17 effector cells while IL-17A, as a single cytokine, may manifest anti- or pro-tumor effects depending on the tumor environment or tumor type. Here, IL17A is linked to neoplasm.